CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

One of the largest benefit managers, CVS Health’s Caremark, made the decision to exclude Zepbound in spite of research that found that it resulted in more weight loss than Wegovy, which will ...

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...

Even if the order takes effect, it will do nothing to address the root causes of the problem it purports to solve.